menu
    • menu
    [{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluocytosine","moa":"Thymidylate synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Tasly BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Flucytosine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Tasly BioPharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Tasly BioPharmaceuticals"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Not Applicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Not Applicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Not Applicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Denovo Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denovo Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluocytosine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"5-Fluorocytosine","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Denovo Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Denovo Biopharma \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Denovo Biopharma \/ California Institute for Regenerative Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals for Flucytosine

    Menu

    Flucytosine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strides Pharma Science

                            India
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

                            Lead Product(s) : Fluocytosine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Strides receives USFDA Approval for Flucytosine Capsules

                            Details : USFDA approved generic version of Flucytosine Capsule (thymidylate synthetase inhibitor) indicated for treating serious infections caused by susceptible strains of Candida and/or Cryptococcus (meningitis and pulmonary infections)

                            Brand Name : Ancobon-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 20, 2020

                            Lead Product(s) : Fluocytosine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Denovo Biopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Denovo Biopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $11.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cirm Awards $11.8 Million Grant for Trial in High-Grade Glioma Using DB107

                            Details : The proceeds will advance the development of DB107, consisting of two components: DB107–RRV as a prodrug activator and DB107–FC as an oral prodrug for high-grade glioma, including glioblastoma.

                            Brand Name : DB107-RRV

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $11.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Denovo Biopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Denovo Biopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of...

                            Details : DB107 (vocimagene amiretrorepvec) is a two-part cancer-selective immunotherapy comprising an investigational gene therapy treatment and an investigational small molecule, which is investigated for the treatment of newly diagnosed high grade glioma.

                            Brand Name : DB107

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 25, 2023

                            Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Transgene

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Transgene

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TG6002,Fluocytosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with ...

                            Details : TG6002 is novel oncolytic virus that has been engineered to combine multiple mechanisms of action. It has been designed to,selectively replicate within cancer cells. This is due to deletion of viral genes encoding TK and RR.

                            Brand Name : TG6002

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : TG6002,Fluocytosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Transgene

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Transgene

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TG6002,Fluocytosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administratio...

                            Details : These data provide a clinical proof of concept for Transgene’s double deleted VVcopTK-RR- patented virus backbone: after IV administration, TG6002 reached the tumor, multiplied within tumor cells, and induced the local expression of its payload (the FC...

                            Brand Name : TG6002

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 09, 2021

                            Lead Product(s) : TG6002,Fluocytosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Transgene

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Transgene

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TG6002,Fluocytosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Data From a Phase 1 Trial With Transgene’s Oncolytic Virus TG6002

                            Details : The trial aims at confirming the good tolerability of ascending doses of intravenous TG6002 and at providing the first translational data from this novel route of administration.

                            Brand Name : TG6002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 08, 2020

                            Lead Product(s) : TG6002,Fluocytosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Transgene

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Transgene

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TG6002,Fluocytosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Tasly BioPharmaceuticals

                            Deal Size : $22.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals

                            Details : Transgene has been a shareholder in Tasly BioPharmaceuticals when it received shares of Tasly Biopharmaceuticals in exchange for the sale of the Greater China rights of T101 and T601, two products respectively incorporating Transgene’s TG6002 and TG105...

                            Brand Name : TG6002

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 04, 2020

                            Lead Product(s) : TG6002,Fluocytosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Tasly BioPharmaceuticals

                            Deal Size : $22.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aurobindo Pharma Limited

                            India arrow
                            Antibody Engineering
                            Not Confirmed

                            Aurobindo Pharma Limited

                            India arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocytosine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aurobindo Pharma Gets USFDA Nod For Flucytosine Capsules

                            Details : Flucytosine capsules are generic version of Bausch Health's Ancobon capsules. The product will be launched in June 2020.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 04, 2020

                            Lead Product(s) : Fluocytosine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth